Cryo-Cell International Inc
Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 240,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Cryo-Cell's stock with a target price of $9, indicating possible future growth.
Financial Health
Cryo-Cell International Inc is performing well with strong revenues and cash flow, indicating solid profitability.
Dividend
Cryo-Cell International Inc offers a high dividend yield of 11.49%, making it appealing for dividend-seeking investors. If you invested $1000, you would be paid $114.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CCEL
Cell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Revenue Model
Processing fees plus annual storage create a subscription-like revenue stream, which can smooth income — though growth depends on new customer sign-ups and retention.
Niche Healthcare Service
Cord blood banking sits at the intersection of consumer health and biotech, with potential demand from future therapies — regulatory and scientific shifts can change the outlook.
Small-cap Dynamics
With a market cap around $35m, the stock can be volatile and thinly traded; this may suit higher-risk, long-term investors but increases capital and liquidity risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
